Sunovion pens $890M Otsuka pact for a clutch of neuropsychiatric drugs

Sunovion pens $890M Otsuka pact for a clutch of neuropsychiatric drugs

Source: 
Fierce Biotech
snippet: 

Sunovion, owned by Japan’s Sumitomo Dainippon Pharma, has signed a near $1 billion upfront/biobucks mix deal with fellow Japanese native Otsuka Pharmaceutical.